SCYL1

Across TCGA pan-cancer cohorts, SCYL1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SCYL1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SCYL1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SCYL1 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where SCYL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCYL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.351	<.001	11	view →
LUAD	Male	II,III,IV	+0.450	<.001	9	view →
LSCC	Female	All	+0.325	<.001	8	view →
CCRCC	All	II,III,IV	+0.076	.004	7	view →
COAD	All	All	+0.075	.005	6	view →
PDAC	Female	All	−0.218	<.001	5	view →
OV	All	All	+0.441	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SCYL1–HNSC

Open the HNSC breakdown →